10:00 AM EST - Labopharm Inc. : provided an update on its previously announced strategic review process, which the Board of Directors , in conjunction with senior management, has undertaken with the objective of maximizing shareholder value. Labopharm believes that its INTELLITAB(TM) and POLYMERIC NANO-DELIVERY SYSTEMS(TM) (PNDS(TM)) technology platforms could have potential in their respective fields of application and are evaluating strategies to capitalize on these assets. As part of the strategic review process, Labopharm is also exploring potential business combinations that could create value for shareholders. There can be no assurance, however, that these actions will result in any specific transaction. Labopharm Inc.
shares T.DDS are trading up $0.01 at $0.41.
